Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

BACKGROUND: This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32(day 1)-35(day 0)weeks of gestational age –wGA-) in Spain. METHODS: A decision-tree model was developed to compare health b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez-Luna, M., Burgos-Pol, R., Oyagüez, I., Figueras-Aloy, J., Sánchez-Solís, M., Martinón-Torres, F., Carbonell-Estrany, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645982/
https://www.ncbi.nlm.nih.gov/pubmed/29041909
http://dx.doi.org/10.1186/s12879-017-2803-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645982/
https://www.ncbi.nlm.nih.gov/pubmed/29041909
http://dx.doi.org/10.1186/s12879-017-2803-0

Ejemplares similares